Home » Topics » Disease categories and therapies » Cardiovascular

Cardiovascular
RSS

Cell Genesys and Collateral Therapeutics collaborate on cardiovascular gene therapy

Dec. 21, 1998

Millennium delivers two drug targets for screening to Lilly

Dec. 18, 1998

RPR and Oxford BioMedica enter collaboration on gene expression control technology

Dec. 18, 1998

Antiarrhythmic agents in early development at Meiji Seika

Dec. 17, 1998

Gene Logic and P&G expand drug discovery collaboration

Dec. 17, 1998

Elastase inhibition as a potential approach to treating acute viral myocarditis

Dec. 16, 1998

Eisai launches new formulation of antiarrhythmic drug in Japan

Dec. 16, 1998

FDA grants expedited development status to Cordox as it begins phase III trials

Dec. 16, 1998

New prostanoid compound from Ono is a useful tool for studying cardiovascular system

Dec. 15, 1998

P&G submits NDA for antiarrhythmic drug azimilide

Dec. 14, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...